

Performance Against Delivery Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure
1	16/EE/0011	194393	Phase III Otonomy Study 104-201508	Number Agreed	1	1	Date Agreed	30/06/2017	2	21/07/2017	2	Recruitment Finished
2	14/EM/0130	149751	NCRN - 2890: Quizartinib (AC220) Monotherapy vs. Salvage Chemotherapy	Number Agreed	3	3	Date Agreed	31/08/2017	6	04/09/2017	6	Recruitment Finished
3	16/EE/0243	207331	A 6 Month Multicentre Phase 3, Open-Label extension Safety Study of OTO-104	Number Agreed	1	1	Date Agreed	30/11/2017	5	06/09/2017	5	Recruitment Finished
4	15/SC/0456	174561	CANC - 4254 - Anti-Pd-L1 Antibody (MPDL3280A) in Pediatric and Young Adult	Number Agreed	2	2	Date Agreed	30/09/2017	1	29/09/2017	1	Recruitment Finished
5	15/LO/2098	182147	CRIT 3822	Number Agreed	6	6	Date Agreed	31/12/2017	9	11/12/2017	9	Recruitment Finished
6	17/NW/0223	219119	Evaluation of PKU explore	Number Agreed	1	1	Date Agreed	31/12/2017	3	27/11/2017	3	Recruitment Finished
7	15/LO/0743	179335	HEPA 4444 (Hep B)	Number Agreed	4	4	Date Agreed	28/08/2018	3	18/09/2017	3	Withdrawn By Sponsor
8	14/EM/0215	152549	NCRN - 3109 Veliparib (ABT-888) in Metastatic or Locally Advanced Unresectable BRCA-Associated Breas	Number Agreed	1	1	Date Agreed	30/11/2017	1	30/11/2017	1	Recruitment Finished
9	13/SC/0173	108971	VIABLE	Number Agreed	6	6	Date Agreed	01/06/2017	15	07/10/2017	15	Recruitment Finished
10	16/EE/0325	204922	Venetoclax (ABT-199) in relapsed/refractory CLL (M15-550)	Number Agreed	4	4	Date Agreed	01/07/2018	3	20/12/2017	3	Recruitment Finished
11	15/LO/0141	169126	OPHT 3845	Number Agreed	4	4	Date Agreed	31/12/2018	0	18/10/2017	0	Withdrawn By Host
12	16/SC/0542	208245	OMASPECT	Number Agreed	1	1	Date Agreed	31/01/2018	2	20/11/2017	2	Withdrawn By Sponsor
13	17/LO/0017	213632	Open-label Extension Study for Participants with Prostate Cancer	Number Agreed	2	2	Date Agreed	31/10/2017	2	01/10/2017	2	Recruitment Finished
14	14/WM/0013	143136	MCRN2947 (ALS-8176-503) Developing a new drug to treat infants hospitalised with RSV infection	Number Agreed	8	8	Date Agreed	31/03/2018	11	31/01/2018	11	Recruitment Finished
15	16/SW/0201	205118	OPHT 5713	Number Agreed	4	4	Date Agreed	31/01/2018	5	07/02/2018	5	Recruitment Finished
16	16/EM/0512	215840	TRILOGY	Number Agreed	4	4	Date Agreed	31/08/2018	4	31/03/2018	4	Recruitment Finished
17	16/NE/0142	202233	CANC 5578 (B9991010)	Number Agreed	5	5	Date Agreed	30/06/2018	2	19/01/2018	2	Recruitment Finished
18	16/SC/0416	210405	Safety and Efficacy of MEDI8897 Against RSV in Healthy Preterm Infants	Number Agreed	4	4	Date Agreed	30/11/2017	1	30/11/2017	1	Recruitment Finished
19	16/LO/1322	208946	RSV-M-301	Number Agreed	20	20	Date Agreed	31/05/2018	2	27/02/2018	2	Withdrawn By Sponsor
20	17/LO/0249	220398	CO39385: Study of Atezolizumab + Enzalutamide vs Enzalutamide in mCRPC	Number Agreed	5	5	Date Agreed	31/05/2018	0	19/04/2018	0	Recruitment Finished
21	16/YH/0450	213782	20150288 - Blinatumomab in DLBCL	Number Agreed	1	1	Date Agreed	31/07/2018	0	27/04/2018	0	Recruitment Finished
22	14/SW/1085	161878	NCRN - 3159	Number Agreed	2	2	Date Agreed	17/03/2018	3	11/05/2018	3	Recruitment Finished

Performance Against Delivery Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure
23	16/LO/0814	199311	CHIL4593 - Sarilumab, administered with subcutaneous (SC) injection, in patients aged 2 to 17, with polyarticular-course juvenile idiopathic arthritis (pcJIA) followed by an extension phase	Number Agreed	1	1	Date Agreed	30/06/2019	0	16/05/2018	0	Recruitment Finished
24	16/NE/0316	207651	Phase 1 Study CYP-001 for the Treatment of Acute Graft vs Host Disease	Number Agreed	2	2	Date Agreed	31/03/2018	2	23/05/2018	3	Recruitment Finished
25	15/LO/0710	177905	EMBARC:MDV3100-13 Phase3, Enzalutamide, nonmetastatic Prostate Cancer	Number Agreed	12	12	Date Agreed	31/12/2019	4	07/06/2018	4	Withdrawn By Sponsor
26	17/EM/0468	234972	A3921104 - Tofacitinib for treatment of Juvenile Idiopathic Arthritis	Number Agreed	1	1	Date Agreed	23/05/2018	0	20/06/2018	0	Recruitment Finished
27	15/EM/0300	180135	CANC 4488	Number Agreed	5	5	Date Agreed	30/06/2018	3	29/06/2018	3	Recruitment Finished
	17/LO/1865	232414	Combination therapy with isatuximab in	Number Agreed	3	3	Date Agreed	31/03/2019	2	29/06/2018	2	Withdrawn By Sponsor
	17/EM/0075	222172	High Energy High Protein Tube Feed	Number Agreed	1	1	Date Agreed	31/05/2018	1	31/05/2018	1	Recruitment Finished
	16/EM/0194	194984	DERM 5311	Number Agreed	50	50	Date Agreed	29/06/2018	50	29/06/2018	50	Recruitment Finished